Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Xavier Leleu, Ajai Chari, Shambavi Richard, Monica Khurana, Akeem Yusuf & Saad Z. Usmani. (2021) A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly. Expert Review of Hematology 14:12, pages 1049-1058.
Read now
Read now
Articles from other publishers (11)
Jumpei Teramachi, Hirokazu Miki, Shingen Nakamura, Masahiro Hiasa, Takeshi Harada & Masahiro Abe. (2023) Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents. Journal of Bone and Mineral Metabolism 41:3, pages 388-403.
Crossref
Crossref
Evert Njomen, Allison Vanecek, Theresa A. Lansdell, Ya-Ting Yang, Peter Z. Schall, Christi M. Harris, Matthew P. Bernard, Daniel Isaac, Omar Alkharabsheh, Anas Al-Janadi, Matthew B. Giletto, Edmund Ellsworth, Catherine Taylor, Terence Tang, Sarah Lau, Marc Bailie, Jamie J. Bernard, Vilma Yuzbasiyan-Gurkan & Jetze J. Tepe. (2022) Small Molecule 20S Proteasome Enhancer Regulates MYC Protein Stability and Exhibits Antitumor Activity in Multiple Myeloma. Biomedicines 10:5, pages 938.
Crossref
Crossref
Tanya R. Porras-Yakushi, Justin M. Reitsma, Michael J. Sweredoski, Raymond J. Deshaies & Sonja Hess. (2021) In-depth proteomic analysis of proteasome inhibitors bortezomib, carfilzomib and MG132 reveals that mortality factor 4-like 1 (MORF4L1) protein ubiquitylation is negatively impacted. Journal of Proteomics 241, pages 104197.
Crossref
Crossref
Aida Varela-Moreira, Demian van Straten, Heleen F. van Leur, Ruud W.J. Ruiter, Anil K. Deshantri, Wim E. Hennink, Marcel H.A.M. Fens, Richard W.J. Groen & Raymond M. Schiffelers. (2020) Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model. International Journal of Pharmaceutics: X, pages 100049.
Crossref
Crossref
Matthew B. Giletto, Pawel A. Osmulski, Corey L. Jones, Maria E. Gaczynska & Jetze J. Tepe. (2019) Pipecolic esters as minimized templates for proteasome inhibition. Organic & Biomolecular Chemistry 17:10, pages 2734-2746.
Crossref
Crossref
Joshua Richter, Noa Biran, Narjust Duma, David H. Vesole & David Siegel. (2017) Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series. Hematological Oncology 35:2, pages 246-251.
Crossref
Crossref
Jonghoon Park, Eok Park, Cheol-Kyu Jung, Seung-Wan Kang, Byung Gyu Kim, Youngjoo Jung, Tae Hun Kim, Ji-Young Lim, Sung-Eun Lee, Chang-Ki Min & Kwang-Ai Won. (2016) Oral proteasome inhibitor with strong preclinical efficacy in myeloma models. BMC Cancer 16:1.
Crossref
Crossref
C O'Connor, F Lohan, J Campos, E Ohlsson, M Salomè, C Forde, R Artschwager, R M Liskamp, M R Cahill, P A Kiely, B Porse & K Keeshan. (2016) The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia. Oncogene 35:40, pages 5272-5281.
Crossref
Crossref
A Keith Stewart. (2015) Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma. Future Oncology 11:15, pages 2121-2136.
Crossref
Crossref
Lixia Wang, Jinfang Zhang, Lixin Wan, Xiuxia Zhou, Zhiwei Wang & Wenyi Wei. (2015) Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacology & Therapeutics 151, pages 141-151.
Crossref
Crossref
Jia Liu, Shavali Shaik, Xiangpeng Dai, Qiong Wu, Xiuxia Zhou, Zhiwei Wang & Wenyi Wei. (2015) Targeting the ubiquitin pathway for cancer treatment. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1855:1, pages 50-60.
Crossref
Crossref